-
1 Comment
Whan In Pharm Co.,Ltd is currently in a long term uptrend where the price is trading 24.1% above its 200 day moving average.
From a valuation standpoint, the stock is 81.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Whan In Pharm Co.,Ltd's total revenue rose by 14.5% to $44B since the same quarter in the previous year.
Its net income has increased by 52.0% to $5B since the same quarter in the previous year.
Finally, its free cash flow fell by 131.0% to $-3B since the same quarter in the previous year.
Based on the above factors, Whan In Pharm Co.,Ltd gets an overall score of 4/5.
Exchange | KO |
---|---|
CurrencyCode | KRW |
ISIN | KR7016580003 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Market Cap | 180B |
---|---|
PE Ratio | None |
Target Price | 21000 |
Dividend Yield | 2.5% |
Beta | 0.33 |
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceuticals products in South Korea. The company offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 016580.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025